Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study

Journal:

Nature Communications

Published:

2026-04-10

DOI:

10.1038/s41467-026-71756-7

Affiliations:

12

Authors:

22

Go to article

Institutions	Authors	Share
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy	11.000000 11.000000	0.50
University of Bari Aldo Moro (UniBA), Italy	4.500000	0.20
Bari University Hospital, Italy	3.500000	0.16
Ceinge - Biotecnologie Avanzate S.C. a r.l., Italy	2.000000	0.09
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", Italy	1.000000	0.05

Interested in Clinical Sciences?